Success Stories: NIW Petition Approved for a Scientist from China in the Field of Biotechnologies in Just 10 Days, Thanks to Our Team’s Efforts and the Premium Processing Service
Client’s Testimonial:
“Thank you. It has been a pleasure to work with the firm, and you have been truly professional and remarkable!”
On August 24th, 2023, we received another EB-2 NIW (National Interest Waiver) approval for a Scientist in the Field of Biotechnologies (Approval Notice).
General Field: Biotechnologies
Position at the Time of Case Filing: Scientist
Country of Origin: China
State of Residence at the Time of Filing: California
Approval Notice Date: August 24th, 2023
Processing Time: 10 days (Premium Processing Requested)
Case Summary:
Based on the huge number of successful cases, North America Immigration Law Group has developed the most up-to-date winning strategies for the NIW category, which enable us to offer our “Approval or Refund” services to many of the NIW cases we take. However, there are certain prerequisites to be fulfilled by an individual, including:
- The foreign national must be in a position to advance the proposed endeavor.
- The applicant must present evidence that the U.S. would benefit on balance to waive the job offer criteria for an EB-2.
- A proposed endeavor, holding substantial merit and national importance.
Our client, a scientist from China, approached us to file an NIW (National Interest Waiver Petition) on his behalf.
He has completed his M.S. in chemical and biomolecular engineering, and as an expert in the field of biotechnologies, his proposed endeavor is to is to investigate novel strategies for diagnosis, drug delivery, and immunotherapy in order to develop new treatments for cancer and improve patient outcomes.
Therefore, to make a persuasive case in his favor, we included the following details in his petition packet:
- His work has resulted in 4 peer-reviewed journal articles (2 of them first-authored), 2 pre-prints (1 of them first-authored), and 2 patent applications (1 of them first-authored).
- His publications have been cited a total of 55 times, according to Google Scholar.
- He has even received 4 recommendation letters from fellow experts in his field of expertise. Out of those, one of the excerpts is mentioned below:
“[Client’s] findings demonstrate a highly versatile novel intracellular delivery platform based on microfluidic cell deformation. The AESOP platform that [client] developed exhibits high intracellular delivery efficiency, high cell viability, and high throughput, and as such is a major first for gene editing platforms. [Client’s] findings thus directly contribute towards the development of the next generation of intracellular gene editing delivery methods with improved safety, efficiency, and clinical efficacy.”
Thus, our client has provided independent researchers from around the world with useful approaches to the study of complex topics within the field of biotechnologies. That other researchers consistently look to his methods and findings to inform and guide their own studies indicates that he is well positioned to make further useful discoveries in the field of biotechnologies.
His research has also been supported with funding from the American Cancer Society, Center for Advanced Design and Manufacturing of Integrated Microfluids, Department of Energy, and the National Science Foundation. This funding is reserved solely for research directed at advancing the national interest, including research that advances the national health, prosperity, and welfare, addresses environmental challenges, and improves the lives of people with cancer.
On that account, he received his NIW approval in just 10 days, thanks to the premium processing service. We wish him good luck in his upcoming endeavor.